| ProteomTech’s
mission is to develop new protein therapeutics
for treating illness, improving health,
and extending longevity.
ProteomTech, Inc. (PTI) is an emerging
product-driven drug development company
focusing on developing and producing therapeutic
proteins through optimally refolding E.
coli inclusion bodies that are difficult
to recover by competing technologies.
Using its robust, patented protein refolding
technology, the Pt-Fold technology, PTI
has developed a pipeline of new protein
drugs. In addition, PTI is using its China
facility for accelerated drug approval
and marketing in China, in turn quickly
validate the clinical development investment
in the US and world market.
PTI has also developed an automated protein
refolding system using the core Pt-Fold
technology. The automated system is capable
of producing a large number of biologically
active human proteins at low cost and
with high throughput. The automated refolding
system enables PTI to serve its customers
with high efficiency and low cost.
|
 |
|
